Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2483-2490

  DeNardo, Gerald L ^a,d   Kroger, Linda A ^a   Meares, Claude F ^b   Richman, Carol M ^a   Salako, Qansy ^a   Shen, Sui ^a   Lamborn, Kathleen R ^c   Peterson, James J ^b   Miers, Laird A ^a   Zhong, Gao Ren ^a   DeNardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 2 IMINOTHIOLANE 2 [4 (BROMOACETAMIDO)BENZYL] 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID; ANTIBODY CONJUGATE; CHELATING AGENT; INDIUM 111; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DOSIMETRY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CHELATING AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 0031784176     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. 111In-labeled monoclonal antitumor antibodies in normal animals and nude-mouse human tumor models. Cancer Res., 43: 5347-5355, 1983.
2. Pimm, M. V., Perkin, A. C., and Baldwin, R. W. Differences in tumor and normal tissue concentrations of iodine and indium labeled monoclonal antibody. II. Biodistribution studies in mice with human tumor xenografts. Eur. J. Nucl. Med., 11: 300-304, 1985.
3. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res., 48: 3270-3275, 1988.
4. Hnatowich, D. J. Antibody radiolabeling, problems and promises. Nucl. Med. Biol., 17: 49-55, 1990.
5. Wessels, B. W., and Rogus, R. D. Radionuclide selection and model adsorbed dose calculations for radiolabeled tumor associated antibodies. Med. Phys., 11: 638-645, 1984.
6. Moi, M. K., Meares, C. F., DeNardo, S. J. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and study of its yttrium (III) complex. J. Am. Chem. Soc., 110: 6266-6267, 1988.
7. Deshpande, S. V., DeNardo, S. J., Kukis, D. L., Moi, M. K., McCall, M. J., DeNardo, G. L., and Meares, C. F. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med., 31: 473-479, 1990.
8. DeNardo, G. L., Kroger, L. A., DeNardo, S. J., Miers, L. A., Salako, Q., Kukis, D. L., Fand, I., Shen, S., Renn, O., and Meares, C. F. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3). Cancer (Phila.), 73 (Suppl.): 1012-1022, 1994.
9. Meares, C. F., Moi, M. K., Diril, H., Kukis, D. L., McCall, M. J., Shrikant, V., Deshpande, V., DeNardo, S. J., Snook, D., and Epenetos, A. A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer, 10: 21-26, 1990.
10. Larson, S. M., and Carrasquillo, J. A. Advantages of radioiodine over radioindium labeled monoclonal antibodies for imaging solid tumors. Nucl. Med. Biol., 15: 231-233, 1988.
11. Li, M., and Meares, C. F. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug. Chem., 4: 275-283, 1993.
12. DeNardo, S. J., O'Grady, L. F., Richman, C. M., and DeNardo, G. L. Overview of radioimmunotherapy in advanced breast cancer using 1-131 chimeric L6. In: R. L. Ceriani (ed.), Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, pp. 203-211. New York: Plenum Press, 1994.
13. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.): 5916-5920, 1995.
14. DeNardo, S. J., Mirick, G. R., Kroger, L. A., O'Grady, L. F., Erickson, K. L., Yuan, A., Lamborn, K. R., Hellstrom, I., Hellstrom, K. E., and DeNardo, G. L. The biologic window for chimeric L6 radioimmunotherapy. Cancer (Phila.), 73 (Suppl.): 1023-1032, 1994.
15. Liu, A. Y., Robinson, R. R., Hellstrom, K. E., Murray, E. D. J., Chang, C. P., and Hellstrom, I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc. Natl. Acad. Sci. USA. 84: 3439-3443, 1987.
16. Fell, H. P., Gayle, M. A., Yelton, D., Lipsich, L., Schieven, G. L., Marken, J. S., Aruffo, A., Hellstrom, K. E., Hellstrom, I., and Bajorath, J. Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site. J. Biol. Chem., 267: 15552-15558, 1992.
17. Howell, L. P., DeNardo, S. J., Levy, N., Lund, J., and DeNardo, G. L. Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int. J. Biol. Markers, 10: 126-135, 1995.
18. Winthrop, M. D., DeNardo, S. J., Muenzer, J. T., Chi, S. G., and Gumerlock, P. H. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer (Phila.), 80 (Suppl.): 2706-2712, 1997.
19. McCall, M. J., Diril, H., and Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem., 1: 222-226, 1990.
20. Penefsky, H. S. A centrifuged-column procedure for the measurement of ligand binding by beef heart F1. Methods Enzymol., 56G: 527-530, 1979.
21. Meares, C. F., McCall, M. J., Reardan, D. T., Goodwill, D. A., Diamanti, C. I., and McTigue, M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem., 142: 68-78, 1984.
22. 111indium-DOTA chelates: a simple and efficient method. Bioconjug. Chem., 5: 101-104, 1994.
23. DeNardo, S. J., Zhong, G-R., Salako, Q., Li, M., DeNardo, G. L., and Meares, C. F. Pharmacokinetics of chimeric L6 conjugated to indium-111 and yttrium-90-DOTA-peptide in tumor bearing mice. J. Nucl. Med., 36: 829-836, 1995.
24. Beaumier, P. L., Neuzil, D., Yang, H. M., Noll, E. A., Kishore, R., Eary, J. F., Krohn, K. A., Nelp, W. B., Hellstrom, K. E., and Hellstrom, I. Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies. J. Nucl. Med., 27: 824-828, 1986.
25. Hui, T. E., Fisher, D. R., Kuhn, J. A., Williams, L. E., Nourigat, C., Bodger, C. C., Beatty, B. G., and Beatty, J. D. A mouse model for calculating cross-organ beta dose from yttrium-90-labeled immunoconjugates. Cancer (Phila.), 73 (Suppl.): 951s-957s, 1994.
26. Coffey, J. L., and Watson, E. E. Calculating dose from remaining body activity: a comparison of two methods. Med. Phys., 6: 307-308, 1979.
27. Loevinger, R., and Berman, M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides. MIRD Pamphlet No. 1, pp. 3-10. New York: Society of Nuclear Medicine, 1976.
28. DeNardo, S. J., Kukis, D. L., Miers, L., Winthrop, M. D., Kroger, L. A., Salako, Q. A., Shen, S., Lamborn, K. R., Gumerlock, P. H., Meares, C. F., and DeNardo, G. L. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J. Nucl. Med., 39: 842-849, 1998.
29. Hollander, M., and Wolfe, D. A. Nonparametric Statistical Methods. New York: Wiley, 1973.
30. DeNardo, G. L., Mirick, G. R., Kroger, L. A., O'Donnell, R. T., Meares, C. F., and DeNardo, S. J. Antibody responses to macrocycles in lymphoma. J. Nucl. Med., 37: 451-456, 1996.
31. Siegel, J. A., and Stabin, M. G. Absorbed fractions for electrons and β particles in spheres of various sizes. J. Nucl. Med., 35: 152-156. 1994.
32. DeNardo, S. J., Richman, C. M., Goldstein, D. S., Shen, S., Salako, Q. A., and Kukis, D. L. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res., 17: 1735-1744, 1997.
33. Hall, E. J. Radiobiology for the Radiologist, pp. 29-43. Philadelphia: J. B. Lippincott Co., 1994.
34. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453-456, 1991.
35. Harris, C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. (Bethesda), 88: 1442-1455, 1996.
36. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC). 253: 49-53, 1991.
37. Lane, D. P. Cancer: p53. guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
38. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C., and Harris, A. L. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
39. DeNardo, S. J., Kukis, D. L., Kroger, L. A., O'Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., and DeNardo, G. L. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc. Natl. Acad. Sci. USA. 94: 4000-4004, 1997.